Biagon Molecular Engineering
About Biagon Molecular Engineering
Biagon develops machine learning solutions that model the conformational space of G protein-coupled receptors (GPCRs) to predict signaling efficacy across various pathways. This approach addresses the complexities of GPCR-targeting campaigns, enabling drug developers to optimize therapeutic outcomes by understanding the molecular mechanisms of receptor activation and inhibition.
```xml <problem> G protein-coupled receptors (GPCRs) are a major class of drug targets, but their complex signaling pathways and conformational changes make it difficult to predict drug efficacy and optimize therapeutic outcomes. Many GPCRs are considered "undruggable" due to challenges in discovering novel chemical matter and understanding their signaling complexity. </problem> <solution> Biagon is developing machine learning solutions that model the conformational space of GPCRs to predict signaling efficacy across various pathways. Their platform, Bronzeville, operates on the principle that the equilibrium of the ligand-induced conformational ensemble is linearly proportional to the activation of cellular signals. By combining biophysics and machine learning, Biagon aims to provide drug developers with powerful tools to address challenges associated with targeting GPCRs, including predicting and untangling their signaling complexity. This approach enables a deeper understanding of the molecular mechanisms of receptor activation and inhibition, leading to optimized therapeutic strategies. </solution> <features> - Machine learning models that predict GPCR signaling efficacy. - Biophysics-based approach to model the conformational space of GPCRs. - Bronzeville platform that links ligand-induced conformational changes to cellular signal activation. </features> <target_audience> The primary customers are drug developers and researchers targeting GPCRs for a wide range of indications. </target_audience> ```
What does Biagon Molecular Engineering do?
Biagon develops machine learning solutions that model the conformational space of G protein-coupled receptors (GPCRs) to predict signaling efficacy across various pathways. This approach addresses the complexities of GPCR-targeting campaigns, enabling drug developers to optimize therapeutic outcomes by understanding the molecular mechanisms of receptor activation and inhibition.
Where is Biagon Molecular Engineering located?
Biagon Molecular Engineering is based in Chicago, United States.
When was Biagon Molecular Engineering founded?
Biagon Molecular Engineering was founded in 2024.
Who founded Biagon Molecular Engineering?
Biagon Molecular Engineering was founded by David Cooper.
- David Cooper - Co-Founder/CEO
- Location
- Chicago, United States
- Founded
- 2024
- Employees
- 6 employees